ALB and chronic kidney disease: In the ZENITH-CKD trial, the ETRAa zibotentan (combined with dapagliflozin) was compared to placebo (plus dapagliflozin) in 449 patients with proteinuric CKD (including 18 IgAN patients) and was found to cause a greater reduction in urinary albumin without significant weight gain (145).